ERBB2 and non-small cell lung carcinoma: Chimeric antigen receptor T-cell (CAR T) therapy development represents a promising therapeutic strategy for HER2-positive non-small cell lung cancer (NSCLC), a subtype accounting for 1–5% of NSCLC cases.